Tocilizumab discontinuation after remission achievement in patients with adult-onset Still’s disease

Hiroya Tamai,Yasushi Kondo,Tsutomu Takeuchi,Yuko Kaneko
DOI: https://doi.org/10.1093/rheumatology/keae179
2024-03-20
Rheumatology
Abstract:Abstract Objectives Tocilizumab, an IL-6 inhibitor, has been proven effective in patients with adult-onset Still's disease (AOSD). This study aimed to clarify whether tocilizumab can be discontinued after achieving remission and to identify factors relevant to its successful discontinuation. Methods Consecutive patients with AOSD diagnosed according to Yamaguchi's criteria from April 2012 to July 2022, who were treated with tocilizumab, were retrospectively reviewed. Results Forty-eight patients with AOSD treated with intravenous tocilizumab, with sufficient information, were included. Thirty-eight patients (79.2%) achieved remission after 6 months of tocilizumab treatment, 12 of whom discontinued tocilizumab during remission. Within 1 year after tocilizumab discontinuation, six patients (50.0%) recurred at a mean of 5.5 months, while the other six (50.0%) remained in remission. Between the non-recurrence and recurrence groups, no difference was found in disease activity at tocilizumab discontinuation (systemic feature score, p = 0.24; ferritin, p = 0.46). While the duration of tocilizumab use was not different (p = 0.32), the interval of tocilizumab administration at tocilizumab discontinuation in the recurrence group was 21 (14–35) days, which tended to be shorter than 35 (28–53) days in the non-recurrence group (p = 0.08). Patients with prednisolone dose < 7 mg/day at last tocilizumab treatment had fewer recurrences than those without (p = 0.001). After recurrence, tocilizumab was resumed in half of the patients, resulting in successful disease control. Conclusions The recurrence rate after tocilizumab discontinuation was 50% in 1 year. Patients who remained in remission with a longer interval of tocilizumab administration and lower prednisolone dose were likely to succeed in the withdrawal of tocilizumab.
rheumatology
What problem does this paper attempt to address?
This paper aims to explore whether Tocilizumab can be discontinued in patients with Adult-Onset Still's Disease (AOSD) after achieving remission and to identify factors associated with successful drug discontinuation. Specifically, the researchers aim to answer the following two main questions: 1. **Can Tocilizumab be safely discontinued in AOSD patients after achieving remission?** 2. **What factors are associated with successful discontinuation of Tocilizumab?** ### Background Information - **Adult-Onset Still's Disease (AOSD)**: An autoinflammatory disease characterized mainly by systemic symptoms. Although the overall prognosis is good, about 10-20% of patients may develop life-threatening complications such as macrophage activation syndrome and disseminated intravascular coagulation. - **Tocilizumab**: An IL-6 receptor inhibitor that has been proven effective in AOSD patients, capable of suppressing systemic inflammation and reducing the dose of glucocorticoids. ### Research Methods - **Study Subjects**: Consecutive patients diagnosed with AOSD and treated with Tocilizumab at Keio University Hospital from April 2012 to July 2022. - **Data Collection**: Clinical data were collected by reviewing medical records. - **Assessment Criteria**: Disease activity was assessed using the Systemic Feature Score (SFS), Pouchot score, and modified Pouchot score. Remission was defined as the absence of Still's disease-related symptoms, normal ESR or CRP, and no need for intensified treatment. Relapse was defined as disease exacerbation requiring an increase in glucocorticoid dose or initiation of biologics. ### Main Findings - **Remission Rate**: 38 out of 48 patients (79.2%) achieved remission after 6 months of Tocilizumab treatment. - **Relapse Rate After Discontinuation**: Among the 12 patients who discontinued the drug, 6 (50.0%) relapsed within 1 year, with an average relapse time of 5.5 months. - **Factors Associated with Successful Discontinuation**: - Patients with a longer Tocilizumab dosing interval (>14 days) at the time of discontinuation had a lower relapse rate. - Patients with a lower glucocorticoid dose (<7mg/day) at the time of discontinuation had a lower relapse rate. ### Conclusion - **High Relapse Rate**: The relapse rate within 1 year after discontinuation was 50%. - **Key Factors for Successful Discontinuation**: Patients with a longer Tocilizumab dosing interval and a lower glucocorticoid dose at the time of discontinuation were more likely to successfully discontinue the drug. ### Future Research Directions - Further studies are needed to validate these findings and explore additional factors influencing successful drug discontinuation. Through this study, the authors provide important references for clinical practice on how to safely discontinue Tocilizumab.